These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 7690777)

  • 1. Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients.
    Wang RH; Phillips G; Medof ME; Mold C
    J Clin Invest; 1993 Sep; 92(3):1326-35. PubMed ID: 7690777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the alternative pathway of complement by calcium-loaded erythrocytes resulting from loss of membrane phospholipid asymmetry.
    Test ST; Mitsuyoshi J
    J Lab Clin Med; 1997 Aug; 130(2):169-82. PubMed ID: 9280144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes.
    Schwartz RS; Tanaka Y; Fidler IJ; Chiu DT; Lubin B; Schroit AJ
    J Clin Invest; 1985 Jun; 75(6):1965-72. PubMed ID: 4008648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane phospholipid organization in pathologic human erythrocytes.
    Lubin B; Chiu D
    Prog Clin Biol Res; 1982; 97():137-50. PubMed ID: 7156165
    [No Abstract]   [Full Text] [Related]  

  • 5. Interaction of phosphatidylserine-phosphatidylcholine liposomes with sickle erythrocytes. Evidence for altered membrane surface properties.
    Schwartz RS; Düzgünes N; Chiu DT; Lubin B
    J Clin Invest; 1983 Jun; 71(6):1570-80. PubMed ID: 6408122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormality of phospholipid transverse diffusion in sickle erythrocytes.
    Zachowski A; Craescu CT; Galacteros F; Devaux PF
    J Clin Invest; 1985 May; 75(5):1713-7. PubMed ID: 3998152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane phospholipid abnormalities in pathologic erythrocytes: a model for cell aging.
    Wagner G; Chiu DT; Schwartz RS; Lubin B
    Prog Clin Biol Res; 1985; 195():237-50. PubMed ID: 4059270
    [No Abstract]   [Full Text] [Related]  

  • 8. Complement activation in sickle cell disease: a liposome model.
    Tomasko MA; Chudwin DS
    J Lab Clin Med; 1988 Aug; 112(2):248-53. PubMed ID: 2969403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red cell membrane remodeling in sickle cell anemia. Sequestration of membrane lipids and proteins in Heinz bodies.
    Liu SC; Yi SJ; Mehta JR; Nichols PE; Ballas SK; Yacono PW; Golan DE; Palek J
    J Clin Invest; 1996 Jan; 97(1):29-36. PubMed ID: 8550846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of membrane phospholipids on activation of the alternative complement pathway.
    Mold C
    J Immunol; 1989 Sep; 143(5):1663-8. PubMed ID: 2527270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
    Marquart HV; Svehag SE; Leslie RG
    J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal membrane phospholipid asymmetry in sickle erythrocytes and its pathophysiologic significance.
    Lubin B; Chiu D; Roelofsen B; Van Deenen LL
    Prog Clin Biol Res; 1981; 56():171-93. PubMed ID: 7330009
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of mechanisms of anemia in mice with sickle cell disease and beta-thalassemia: peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylserine exposure.
    Kean LS; Brown LE; Nichols JW; Mohandas N; Archer DR; Hsu LL
    Exp Hematol; 2002 May; 30(5):394-402. PubMed ID: 12031645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in the contents of membrane phospholipid and membrane phospholipid asymmetry in glucose-6-phosphate dehydrogenase deficient erythrocyte].
    Zou C; Tian X; Yan H
    Zhonghua Xue Ye Xue Za Zhi; 1998 Apr; 19(4):192-4. PubMed ID: 11243134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
    Mold C; Walter EI; Medof ME
    J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats.
    Jain SK
    J Clin Invest; 1985 Jul; 76(1):281-6. PubMed ID: 4019780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation.
    Seya T; Hara T; Matsumoto M; Akedo H
    J Immunol; 1990 Jul; 145(1):238-45. PubMed ID: 1694203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormality of erythrocyte membrane n-3 long chain polyunsaturated fatty acids in sickle cell haemoglobin C (HbSC) disease is not as remarkable as in sickle cell anaemia (HbSS).
    Ren H; Ghebremeskel K; Okpala I; Ugochukwu CC; Crawford M; Ibegbulam O
    Prostaglandins Leukot Essent Fatty Acids; 2006 Jan; 74(1):1-6. PubMed ID: 16314081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations.
    Wood BL; Gibson DF; Tait JF
    Blood; 1996 Sep; 88(5):1873-80. PubMed ID: 8781447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.